top of page
  • Recruiting

NCT03689595: PROMISE - Predicting Progression of Developing MM in a High-Risk Screened Population

Updated: Sep 24, 2022

PROMISE


NCT03689595: PROMISE - Predicting Progression of Developing MM in a High-Risk Screened Population


PROMISE STUDY DANA FARBER


The PROMISE Study aims to establish a prospective cohort of individuals with precursor conditions to multiple myeloma, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). We will study these patients as a means to identify risk factors for progression to symptomatic multiple myeloma.


Sponsor

Dana-Farber Cancer Institute


Collaborator

Stand Up To Cancer

 

ClinicalTrials.gov Identifier: NCT03689595

Official Title: Predicting Progression of Developing Myeloma in a High